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Abstract 
To describe temporal trend and characteristics of newly HIV-diagnosed patients in a medical care area in 
Northwest Spain over the last 10 years. All newly diagnosed patients for HIV-infection from 2004 to 2013 at 
a reference medical care area in Northwest of Spain were identified. Epidemiological, virological, 
immunological, and clinical data, as well as HIV genotype and drug resistance information were recorded. A 
total of 565 newly HIV-diagnosed patients were identified. The number of new cases increased in the last 5 
years (66 cases/year). Overall, 53.1% had a median CD4 counts < 350 cells/µl and 33.6% had an AIDS 
defining criteria. Non-B variants were found in 34.4% of patients being subtype F (25.8%) the most common 
non-B subtype. The rate of transmitted drug resistance (TDR) over the study period was 3.7%, but a 
decreased to 2.6% was observed in the last 5 years. The most prevalent TDR mutations were: T215 revertants 
(1.5%), K219QENR (1.2%), for NRTIs; K103N (1.9%), for NNRTIs; L90M (0.3%), for PIs. Overall, 73.2% 
of patients started antiretroviral treatment and 9.9% of patients died during follow-up. The number of newly 
HIV diagnosed patients increased since year 2009. There is a high prevalence of late diagnosis (53%) and 
33% had an AIDS defining criteria. Interestingly, the most prevalent non-B subtype in our population was F 
(25.8%). These findings support the need to facilitate the access for HIV testing to reduce the rate of late HIV 
diagnosis, improve the clinical outcome and prevent HIV transmission. 
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INTRODUCTION 
HIV infection continues to be an important health problem worldwide. It is estimated that more 
than 35 million people are living with HIV; more than 2 million new infections are recorded 
worldwide and 1.5 million people die each year from causes related to HIV infection 
[WHO/UNAIDS, 2013]. In Spain, a total of 25,731 new HIV patients were notified from 2003, 
with annual rates per 100,000 populations that vary from 9.8 in 2003 to 12.2 in 2010 [Ministry of 
Health, Spain, 2013]. With the introduction of highly active antiretroviral therapy (ART), HIV-1 
infection is now manageable as a chronic disease in patients who have access to medication and 
who achieve durable virologic suppression [Palella et al., 1998]. 
 
It is estimated that in Europe, almost 30% of HIV-infected persons still remain undiagnosed 
with an overall incidence of late presentation around 50% of all HIV cases [Scognamiglio et al., 
2013]. These high rates play an important role because late presentation of HIV infection is 
associated with shorter survival, slow and poor response to treatment, higher frequency of ART 
toxicity, increased healthcare costs and rates of HIV transmission [Moreno et al., 2010; Sabin et 
al., 2010; Camoni et al., 2013]. 
 
Moreover, other factors may also have an important role in the management of HIV infection. 
This is the case of the extraordinary genetic variability which characterizes HIV infection with a 
potential impact on disease progression, diagnosis, therapy, and epidemiology [De Felipe et al., 
2011]. HIV epidemic is characterized by a high genotypic diversity and several HIV subtypes and 
circulating recombinant forms (CRFs) have been described [Walèria-Aleixo et al., 2008; Luft et 
al., 2011; Schrrer et al., 2011]. HIV-1 subtype B is predominant in North America and Western 
Europe, including Spain, although is responsible for only 10% of global infections [Luft et al., 
2011; Scherrer et al., 2011]. However, the prevalence of HIV-subtypes varies greatly depending 
on the geographic region, partially because migration produced in the last decade has contributed 
to the current spread of non-B subtypes in developed countries [De Felipe et al., 2011; Luft et al., 
2011]. Although the impact of drug resistance mutations on ART management have been well 
characterized in HIV-1 subtype B infected patients in the developed world, less data are available 
regard non-B subtypes [Johnson et al., 2008]. Thus, resistance against antiretroviral drugs in 
previously untreated HIV patients is of growing relevance. It has been hypothesized that a wide 
use of antiretroviral drugs could result in an increase in drug-resistant virus transmission and more 
generally in the prevalence of resistance variants [Sagir et al., 2007]. Overall, the prevalence of 
TDR varies between 9–24% in Europe and 3–15% in Spain, with the highest TDR rates for both 
nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) followed by protease inhibitors (PIs) [Sagir et al., 2007; Bracciale et al., 
2009; Wittkop et al., 2011; Monge et al., 2012, 2014]. 
 
Therefore, to establish the best strategies for HIV diagnosis, prevention and treatment it is 
important to get a deep knowledge of the characteristics of newly HIV infections in our medical 
setting. Thus, the objective of this study was to analyze the clinical, virological, and 
immunological characteristics in a cohort of newly HIV-1 diagnosed patients in the last 10 years. 
The prevalence of HIV-1 subtypes, drug resistance mutations associated to protease and reverse 
transcriptase inhibitors and factors associated to clinical outcome (response to ART and mortality) 
were also evaluated. 
  
METHODS 
All newly diagnosed patients for HIV infection from January 2004 to December 2013 at the 
medical area of A Coruña, in the northwest of Spain, were recorded. This reference area attends 
more than 500,000 citizens. Factors included in our analysis were epidemiological and clinical 
characteristics at diagnosis, immunological and virological status, HIV-1 subtype, and TDR. 
Characteristics of ART and mortality were also evaluated. 
 
Late diagnosis was defined as CD4 count < 350 cells/mm3 at HIV diagnosis and/or an AIDS-
defining event at presentation. The presence of AIDS was defined according to the Centers for 
Diseases Control and Prevention (CDC) as the presence of CD4 count < 200 cells/mm3 and/or 
clinic category C. 
 
Resistance testing was performed following the recommendations of HIV treatment guidelines 
in force at the moment of starting ART. Both HIV protease and reverse transcriptase were 
amplified from plasma samples using TruGene HIV-1 Genotyping Test (Siemens). FASTA format 
sequences from the HIV protease and reverse transcriptase were obtained and HIV-1 subtypes 
were assigned using the freely available algorithm from Stanford University Drug Resistance 
Database (http://hivdb.stanford.edu/hiv/). 
 
The presence of resistance-associated mutations was evaluated following the Antiretroviral 
Resistance Guidelines, from the Spanish AIDS Research Network, updated in 2013 [De Mendoza 
et al., 2009a]. 
 
This research protocol was approved by the regional ethics committee (“Comité Ético de 
Investigación Clínica de Galicia,” register code 2013/247). 
 
The statistical analysis was performed using the Statistical Package for the Social Sciences 
software (SPSS 19.0, Chicago, IL). Categorical variables are presented as number of cases or 
percentage and were compared by the χ2 test or Fisher's exact test, when appropriate. Continuous 
variables are expressed as median (interquartile range, IQR) and compared by non-parametric 
Mann–Whitney and Kruskal–Wallis test, when appropriate. Multivariate logistic regression 
analysis was used to identify factors independently associated with response to ART. 
Epidemiological characteristics, HIV status at diagnosis and ART regimen were included in 
univariate analysis but only covariates statistically associated with response to ART in univariate 
analysis were included in multivariate logistic regression. Cox regression was used to identify 
factors associated with mortality. Epidemiological characteristics, HIV status at diagnosis and use 
of ART were included in univariate analysis and covariates statistically associated with mortality 
in univariate analysis were included in Cox regression. A P-value of <0.05 was considered 
statistically significant. 
RESULTS 
Epidemiologic Characteristics 
A total of 565 newly HIV diagnosed patients were identified. Table I describes 
epidemiological, immunological, virological, and clinical characteristics of the study population at 
the diagnosis time. The number of new HIV-diagnoses increased significantly from 47 cases/year 
in period 2004–2008 to 66 cases/year in period 2009–2013 (P < 0.001). The distribution of new 
diagnoses per year is shown in Figure 1. The changes in the routes of transmission in the study 
period are shown in Figure 2. Interestingly, new HIV infections in men who have sex with men 
(MSM) have showed a great increase in the last 5 years, while a remarkable decrease among 
heterosexual and intravenous drug users (IDU) is observed since 2011 and 2006, respectively. 
When comparing 5-year periods 2004–2008 and 2009–2013, a significant decreasing in new HIV 
infections among heterosexual (50.9% vs. 37.4%) and IDU populations (19% vs. 8.3%) and an 
increasing among MSM (30.1% vs. 54%) (P < 0.001) was observed. 
Table I. Baseline Characteristics of the Study Population 
Variables N = 565 
Demographic-epidemiological 
Male 468 (83%) 
Age (years) 37 (30–44) 
Routes of HIV transmission 
Heterosexual 228 (43.2%) 
MSM 206 (39%) 
IDU 93 (17.6%) 
Vertical transmission 1 (0.2%) 
Nationality 
Spanish 475 (79%) 
European 18 (3.2%) 
South-American 84 (14.9%) 
North-American 2 (0.4%) 
Asian 1 (0.2%) 
African 13 (2.3%) 
HIV status 
Median CD4 (cells/µl) 344 (128–550) 
CD4 count <350 cells/µl 295 (53.1%) 
Median RNA-HIV log (copies/ml) 4.98 (4.4–5.4) 
Clinical presentation at diagnosis 
No symptoms 363 (66.4%) 
Primary infection 36 (6.5%) 
Non-AIDS defining disease (clinical category B) 44 (8%) 
AIDS defining disease (clinical category C) 105 (19.1%) 
Co-infections 
HBsAg positive 12 (2.1%) 
Anti-HCV positive 112 (19.9%) 
Sexual transmitted diseases 39 (9.1%) 
  
 
Data are n (%) or median (interquartile range). 
  
 
 
 
Figure 1. Distribution of newly HIV diagnosed patients per year of follow-up. 
 
 
 
Figure 2. Distribution of new HIV-diagnoses per routes of transmission and 
year of diagnosis. 
HIV Clinical Status 
The median CD4 cell count and plasma HIV-RNA level at the time of HIV-diagnosis were 344 
(128–550) cells/µl and 4.98 (4.4–5.4) log copies/ml, respectively. Overall, 295 patients (53.1%) of 
the new HIV infections were late diagnoses and 183 patients (33.6%) of newly-diagnosed HIV 
patients had an AIDS defining criteria. The prevalence of late diagnosis was stable comparing 5-
year periods 2004–2008 and 2009–2013 (56.1% vs. 50.9%, respectively, P = 0.229) as well as the 
percentage of patients with AIDS (35.4% vs. 32.4%, respectively, P = 0.467). The most prevalent 
AIDS defining diseases at diagnosis were: Pneumocystis jiroveci pneumonia (41.3%), tuberculosis 
(21.1%), lymphoma (5.8%), toxoplasmosis (4.8%), HIV encephalopathy or progressive multifocal 
leukoencephalopathy (3.8%), wasting syndrome (3.8%), esophageal candidiasis (2.9%), atypical 
mycobacteria infection (1%), other syndromes (15.5%). 
  
HIV Genotypic Subtypes 
The HIV subtype was available for 314 patients (55.6%), of whom 108 subjects (34.4%) were 
infected with HIV-1 non-B subtypes. Significance increased in the prevalence of non-B subtypes 
within the last 5 years from 27.8% in 2009 to 41.3% in 2013 has been observed. Subtype F was the 
most prevalent non-B subtype (25.8%). The HIV subtypes distribution in the study population is 
shown in Figure 3. Of note, MSM transmission was responsible of 79.2% of newly HIV-patients 
with subtype F while subtype B and other non-B/F variants were transmitted by heterosexual 
(47.3% and 54.2%, respectively) and MSM route (47.3% and 41.7%, respectively). Among the 
IDU population, new HIV infections corresponded in a 10.1% to subtype B, 1.3% to subtype F and 
4.2% to other HIV-variants. Significant differences in the route of transmission between HIV-
subtypes were observed (P < 0.001). 
 
 
 
Figure 3 Distribution of HIV-1 subtypes and CRFs. 
Transmitted Drug Resistance Mutations 
Genotypic resistance testing was performed in 323 patients (58.1%). Table II shows the 
prevalence of mutations according to the list of TDR identified for treatment-naïve HIV infected 
patients. The overall prevalence of TDR in this population was 3.7%. The most prevalent TDR 
mutations were: T215 revertants (1.5%), K219QENR (1.2%), for NRTIs; K103N (1.9%), for 
NNRTIs; L90M (0.3%), for PIs. Regarding to antiretroviral drug families, the prevalence of TDR 
mutations was 2.5%, 2.5% and 0.3% for NRTIs, NNRTIs and PIs, respectively. Overall, three 
patients (0.9%) had TDR mutations only for NRTIs, three patients (0.9%) for NNRTIs, 1 patient 
(0.3%) for PIs and five patients (1.6%) had TDR mutations for both NRTIs and NNRTIs. Figure 4 
shows the overall prevalence of TDR and by drug class between 2004–2008 and 2009–2013. 
Decreasing rates of TDR was observed from 10.2% (2004–2008) to 2.6% (2009–2013) in the last 
5 years (P = 0.023). However, there were no significant differences in the prevalence of mutations 
specifically associated with NRTIs, NNRTIs or PIs resistance comparing the two 5-year periods 
but there was a trend to decreasing rates in the last 5 years. Within the last 5 years (2009–2013), 
the annual prevalence of transmitted drug resistance (NRTIs, NNRTIs, and PIs mutations) was less 
than 5% and no clear downward trend was observed in this period. 
  
Table II. Prevalence of TDR Mutations in Newly Diagnosed HIV-Infected Patients 
NRTIs mutations, n (%) NNRTIs mutations, n (%) PIs mutations, n (%) 
 
M41L 1 (0.3) L100I 0 (0) L23I 0 (0) 
K65R 1 (0.3) K101EP 1 (0.3) L24I 0 (0) 
D67EGN 2 (0.6) K103NS 6 (1.9) D30N 0 (0) 
T69D 1 (0.3) V106AM 1 (0.6) V32I 0 (0) 
K70ER 0 (0) V179F 0 (0) M46IL 0 (0) 
L74IV 0 (0) Y181CIV 0 (0) I47AV 0 (0) 
V75AMTS 0 (0) Y188CHL 3 (0.9) G48MV 0 (0) 
F77L 0 (0) G190AES 0 (0) I50LV 0 (0) 
Y115F 1 (0.3) P225H 0 (0) F53LY 0 (0) 
F116Y 0 (0) M230IL 0 (0) I54ALMSTV 0 (0) 
Q151M 0 (0)     G73ACST 0 (0) 
M184IV 1 (0.3)     L76V 0 (0) 
L210W 0 (0)     V82ACFLMST 0 (0) 
T215REVa 5 (1.5)     N83D 0 (0) 
T215YF 0 (0)     I84ACV 0 (0) 
K219ENQR 4 (1.2)     I85V 0 (0) 
        N88DS 0 (0) 
        L90M 1 (0.3) 
      
 
aREV:C/D/E/I/N/S/V. 
 
 
 
Figure 4. Rates of TDR mutations in periods 2004–2008 and 2009–2013. 
  
Antiretroviral Treatment and Mortality 
Overall, 413 patients (73.2%) started ART. The median of CD4 count at the beginning of ART 
was 207 (76–317). The regimen of ART was based on: 2 NRTIs + 1 NNRTIs (45.7%); 2 
NRTIs + 1 PIs (46.7%); 2 NRTIs + integrase inhibitor (5.2%), and other regimens (2.4%). The 
median time from HIV diagnosis to ART initiation was 3 (1–17) months. Overall, after 48 weeks 
of ART, 65% achieved undetectable viremia (HIV-RNA < 20 copies/ml). In multivariate analysis, 
after adjusting for sex, the presence of HIV viral load < 100,000 copies/ml at the time of diagnosis 
(OR 2.3 [1.3–3.9], P = 0.001) and heterosexual transmission (OR 2.5 [1.4–4.6], P = 0.007) were 
significantly associated with virological response to ART; while PIs regimen was associated with 
lower virological response (OR 0.5 [0.3–0.8], P = 0.005). 
 
During follow-up, 56 patients (9.9%) died, and the death occurred during hospitalization at 
HIV-diagnosis in 18 patients (3.2%). The median time from HIV diagnosis to death was 26 (6–42 
months). In multivariate analysis, after adjusting for sex, age (HR 1.04 [1.019–1.065], P < 0.001) 
and the presence of an AIDS-defining disease at the time of diagnosis (HR 7.1 [3.5–14.3], 
P < 0.001) were significant associated with mortality; regarding the use of ART and mortality, to 
achieve undetectable viremia (HIV-RNA < 20 copies/ml) was significant associated with a lower 
risk of mortality (HR 0.04 [0.02–0.1], P < 0.001). 
DISCUSSION 
This study evaluates the characteristics of a large cohort of newly HIV diagnosed patients in 
Northwest of Spain in the last 10 years. A significant increase in the number of new HIV 
diagnosed patients was observed, from 47 cases/year in period 2004–2008 to 66 cases/year in the 
last 5 years. HIV epidemic affects mainly young (median age of 37 years) male (83%) being 
sexual transmission the main route of infection (82%). In the last 10 years, intravenous drug users 
have become a secondary route of transmission while a significant predominance of HIV infection 
among MSM has been observed. The increase in new HIV-infections observed in our population 
could be related to the high prevalence of MSM since year 2009, similarly to the significant 
increase on the HIV prevalence among MSM described in Europe and North America [Van 
Griensven et al., 2009; WHO/UNAIDS, 2013]. Moreover, high-risk sexual behavior among MSM 
described in recent years, as well as MSM are more likely to get tested for HIV might explain the 
increase in new HIV-infections in the last 5 years [Camoni et al., 2013; Fernández-Dávila et al., 
2013]. 
 
High rates of late HIV diagnosis was observed in our study population since half of them 
(53.1%) had CD4 counts < 350 cells/µl and 33.6% had an AIDS defining criteria at the time of 
diagnosis. Reducing late HIV diagnosis is considered a public health priority and continues to be a 
great challenge in most countries [Phillips et al., 2007; Palacios et al., 2008; Dolpech et al., 2013; 
Shen et al., 2013]. To gain this goal, the US CDC and the US Preventive Services Task Force 
(USPSTF) newly recommended one-time HIV testing for persons aged 15–65 at least once as part 
of routine health care [Branson et al., 2006; Moyer, 2013]. In Spain, HIV testing is generally 
performed in case of risk behavior or clinical suspicion, but is not incorporated as a routine 
screening. The high proportion of late presenters at HIV diagnosis observed in our study is similar 
to that reported in other European countries and in Spain [European Centre for Disease Prevention 
and Control, 2010; Palacios et al., 2008]. Of note, the rate of late HIV diagnosis (CD4 
counts < 350 cells/µl) and AIDS events was stable during all the study period. Therefore, it is 
critical to identify the characteristics of new HIV infections to establish optimal strategies for 
prevention and earlier HIV diagnosis [Camoni et al., 2013; Loconsole et al., 2013]. 
  
The identification of HIV-1 subtypes allows us to know the dynamics of HIV molecular 
epidemiology and different transmission or disease progression rates have been suggested [Zhang 
et al., 2010; Hemelaar et al., 2011]. Broad distribution of HIV-1 subtypes worldwide has been 
stable over time, with a prevalence for subtype B of more than 90% in Western Europe and the 
United States [Hemelaar et al., 2011; Luft et al., 2011]. However, the prevalence of non-B 
subtypes in Europe has increased during the last two decades and is mainly related to population 
movements. Although non-B subtypes were more common in people of non-Caucasian origin, 
their estimated prevalence in some European countries is more than 15% in Caucasians; similarly, 
in native Spaniards, the rate of non-B subtypes increased from 1.5% in 2000–2002 to 11% in 
2007–2010 [Bracciale et al., 2009; Treviño et al., 2011; Monge et al., 2012; Abecasis et al., 2013; 
Chaix et al., 2013]. 
 
The prevalence of non-B subtypes observed in our population (34%) is much higher than the 
prevalence described in other Spanish cohorts as the Spanish AIDS Research Network Cohort-
CoRIS (15.9%) and with a HIV subtypes distribution also different. While the rates of CRFs 
account for almost 10% of all HIV infections in Spain, being CRF02_AG the most common non-B 
variant with a prevalence of 40% in Madrid [De Mendoza et al., 2009b; Treviño et al., 2011; 
Monge et al., 2012], the prevalence of CRFs in our population is much lower (3%). Instead, 
subtype F, that causes less than 1% of infections worldwide and 1.6% of newly HIV-diagnoses in 
CoRIS, affects one in four of the newly HIV-diagnosed patients in our study [Hemelaar et al., 
2011; Luft et al., 2011; Monge et al., 2012]. The prevalence reported for subtype F varies between 
different geographic regions and overall is less than 5% but there are some exceptions. In Brazil, 
subtype F accounts for approximately 10–20% of non-B virus infection [Dias et al., 2009; 
Hemelaar et al., 2011]. Moreover, Romania has the highest prevalence described (>70%) due to 
parenteral transmission in children in the late 1980s [Apetrei et al., 1998]. This association with 
demographic parameters suggests highly compartmentalized epidemics, determined by social and 
behavioral characteristics of the patients [Abecasis et al., 2013]. 
 
Observational evidence suggests that non-B subtypes are more able to transmit by the 
heterosexual route [Yirrell et al., 2008; Lai et al., 2012]. In fact, it has been recently described the 
spread of subtype F among Italian heterosexual men and up to 68% of the subtype F Brazilian 
patients were women being infected by heterosexual route [Monteiro et al., 2009; Lai et al., 2012]. 
However, subtype F is mainly transmitted by homosexual route in our study (79.2%). Indeed, a 
rapid expansion of subtype F among MSM in Galicia was reported in HIV newly diagnosed 
patients during 2010–2011 and the phylogenetic analyses traced the ancestry of this cluster in 
Brazil, where the prevalence of subtype F is also high [Thomson et al., 2012]. The recognition of a 
high prevalence of subtype F in our population might be an important issue since more rapid 
disease progression, lower genetic barrier to drug resistance and different response to antiretroviral 
therapy among non-B subtypes has been described [Yirrell et al., 2008; Chaix et al., 2013; Pernas 
et al., 2014]. 
 
HIV treatment guidelines recommend performing an HIV drug resistance testing for all 
subjects beginning treatment [EACS, 2013; DHHS 2014]. Transmission of drug-resistant HIV 
variants is well documented and is associated with suboptimal virologic response to first-line 
antiretroviral treatment, limiting the therapeutic options [Sagir et al., 2007; Bracciale et al., 2009]. 
Overall, the prevalence of TDR varies between 9–24% in Europe and 3–15% in Spain [Wittkop et 
al., 2011; Monge et al., 2012, 2014]. While a stable or declining prevalence of TDR was detected 
in some studies, others showed an increase in TDR prevalence [Sagir et al., 2007; Monge et al., 
2012; Rodriguez-Rodrigues et al., 2013]. Overall, a significant decrease in TDR was observed 
from 10.2% at period 2004–2008 to 2.6% at period 2009–2013. 
 
In Spain, the TDR rate for NNRTIs has decreased from 5.2% in 2007 to 2.8% in 2011 in naïve 
patients, but not for TDR associated with both NRTIs and PIs [Monge et al., 2012, 2014]. In our 
population, during the last 5 years it has been observed a decrease in the rates of TDR for NRTIs 
(6.1% in 2004–2008 to 1.8% in 2009–2013), NNRTIs (6.1–1.8%) and PIs (2–0%) (Fig. 4). 
Moreover, in the CoRIS cohort, patients infected by non-B subtypes were at 73% of lower risk of 
having resistance to the NRTIs class [Walèria-Aleixo et al., 2008; Monge et al., 2012]. It has been 
proposed that changing features in the HIV-1 epidemic in European countries, characterized by a 
significant increase in non-B subtypes from populations migrating from countries with more 
limited access to ART, may partially justify the finding of a reduced prevalence of some TDR 
during the last years [Bracciale et al., 2009; De Mendoza et al., 2009b]. 
 
This low prevalence of TDR may influences treatment and diagnostic recommendations in the 
near future. In fact, some experts have suggested that might not be necessary to perform a baseline 
PIs resistance test, and only evaluate the presence of TDR for NNRTIs could be more cost-
effective in Spain [Monge et al., 2012, 2014] given the cost-benefit for performing genotypic 
studies in naive patients have been established for a TDR prevalence above 5% [Sax et al., 2005]. 
This could be an interesting approach in our population because the global prevalence of TDR is 
3.7% with a significant decrease in the last 5 years with a trend toward decreasing rates of NRTIs, 
NNRTIs, and PIs resistance. 
 
Although some of our results are similar to those described in other studies, specific 
characteristics of our population, as the high prevalence of subtype F, could not be extrapolated to 
other regions in Spanish or European countries. These different features may have important 
implications in our daily clinical practice for the management of HIV-infected patients. One of the 
limitations of our study is the lack of the protease and reverse transcriptase sequences for all the 
study population and therefore the impossibility to determine the HIV subtype, particularly in the 
period 2004–2008 when to perform a genotypic HIV resistance test prior ART initiation was not 
mandatory [Vandamme et al., 2004; Recommendations from GESIDA, 2007]. 
 
In summary, new HIV infections increased in the last 5 years in the Northwest of Spain with a 
high prevalence of late diagnosis and AIDS events. These data highlights the need for a more 
active HIV testing in our population to promote early HIV diagnosis. Moreover, there is a high 
prevalence of subtype F in newly HIV diagnosed patients, being MSM the main route of 
transmission. These findings might be highly relevant for the clinical management of these 
patients and to establish the most optimal strategies for prevention and diagnosis. 
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